NK NKTX Nkarta, Inc. Loading... : Investor Sentiment and Bull/Bear Views

The author is long Nkarta ahead of the ACR Conference readouts from the NTRUST-1/2 trials in myositis and scleroderma, expecting efficacy and durability data plus a safety presentation. He argues the stock trades at $2.56 below cash value with a healthy pipeline progressing toward FDA approval, a 3-year cash runway, no debt, and no sensitivity to interest rate forecasts. The concrete catalyst is the November readout, and he plans to add to his 180,000-share position before it. Main risk implied is clinical/readout failure, though not explicitly stated.

The author is long Nkarta, arguing the stock trades at $2.77 below cash value with a healthy pipeline heading toward FDA approval. The catalyst is the November ACR conference readout of NTRUST-1/2 trial results in myositis and scleroderma, including a safety presentation and durability data. Management (CEO Paul Hastings and the President) reinforced confidence at Stifel's investor forum. The author holds 150,000 shares and plans to add ahead of the readout; main risk is clinical/readout failure, though not explicitly stated.